Advances

NewYork-Presbyterian

Advances in Psychiatry

Home to the country’s top psychiatrists who are leading the field in patient care, research, and medical education.

Last year, we provided care for 20,000 patients and trained 100 residents. Our academic partners — Weill Cornell Medicine and Columbia University Vagelos College of Physicians and Surgeons — are consistently ranked No. 1 in NIH funding. With nationally recognized psychiatrists and psychologists across two academic medical center campuses, we can offer robust specialized programs, such as Addiction & Substance Use Rehabilitation, Geriatric Psychiatry, and Ketamine therapy, to respond to our community’s needs.

image of pregnant woman holding cannabis leaf

Cannabis Use Disorder Rising Significantly During Pregnancy

Columbia and Weill Cornell Medicine researchers report their findings in JAMA Psychiatry that cannabis use disorders increased 150 percent in prenatal hospitalizations from 2010 to 2018.

TMS uses functional magnetic resonance imaging (fMRI) for individual brain mapping

Expanding Research in Personalized Treatments for Depression

Weill Cornell Medicine receives a three-year grant to further develop targeted approaches, such as transcranial magnetic stimulation, for the treatment of refractory depression.

image of elderly man with hand holding up head and looking down

Weathering the Storm: Emotion Regulation App Aids in Suicide Prevention

Weill Cornell Medicine psychologists and psychiatrists develop a psychosocial intervention for middle-aged and older adults at high suicidal risk to bring therapy to them outside of formal therapy sessions.

Columbia psychiatrists take part in a phase 2b clinical trial of psilocybin – a psychedelic compound in magic mushrooms.

Exploring the Potential of Psychedelic Therapy to Improve Depressive Symptoms

Columbia psychiatrists take part in a phase 2b clinical trial of psilocybin – a psychedelic compound in magic mushrooms.

image of Columbia Psychiatry Pathways mobile depression treatment app

Mobile Depression App Provides Point-of-Care Treatment Algorithms

Columbia Psychiatry faculty have developed an interactive smartphone application to strengthen clinicians’ ability to provide outpatient mental health services.

image of cadb westchester building

Stephen Kanne, PhD Brings Innovative Approaches to Autism Care at CADB

Spearheaded by Stephen M. Kanne, PhD, the Center for Autism and the Developing Brain blends world-class psychiatry and autism expertise to bring the latest evidence-based approaches to the diagnosis and treatment of ASD.

image of anxiety cells

‘Anxiety Cells’ Identified in the Brain’s Hippocampus

Neuroscientists at Columbia University Medical Center and the University of California, San Francisco, have found in mice that certain brain cells in the hippocampus fire when the animal is anxious, triggering anxiety-related behaviors.

image of Dr. Mark Olfson

Opioid Overdose Survivors Face Higher Death Rate

Researchers at NewYork-Presbyterian/Columbia have found opioid overdose survivors are at great risk of dying from respiratory diseases, viral hepatitis, and suicide in the year after an overdose, according to a report published in JAMA Psychiatry.

image of Dr. Jonathan Avery

Online Databases: A Prescription for the Opioid Epidemic

As drug overdoses continue to rise in the United States, doctors and policymakers search for solutions to stem the tide of opioid-related deaths. Researchers at NewYork-Presbyterian/Weill Cornell are studying the efficacy of statewide online databases to track prescriptions.

image of Dr. Conor Liston

Defining Unique Subtypes in Depression

In a quest to better define depression diagnosis, a neuroscientist and psychiatrist at NewYork-Presbyterian/Weill Cornell used fMRI brain scans to identify unique subtypes of depression. The study may help physicians to better diagnose depression subtypes and determine which patients would benefit from TMS.

image of Dr. J. John Mann

The Role of Ketamine in Treatment-Resistant Depression

It is estimated that by 2030 depressive illness will account for more disability than any other illness worldwide. Investigators at NewYork-Presbyterian/Columbia are studying the use of ketamine as a treatment option for reducing suicidal thoughts in patients with refractory depression.

Newsletters for Medical Professionals

2022 Issue 1

2021 Issue 2

2021 Issue 1

2020 Issue 1

2019 Issue 1

2018 Issue 3

2018 Issue 2

2018 Issue 1

2017 Issue 2

2017 Issue 1

2016 Issue 3

Spring 2016